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Identifying asymptomatic older individuals at elevated risk for developing Alzheimer’s disease 
(AD) is of clinical importance. Among 1,081 asymptomatic older adults, a recently validated 
polygenic hazard score (PHS) significantly predicted time to AD dementia and steeper 
longitudinal cognitive decline, even after controlling for APOE ε4 carrier status. Older individuals 
in the highest PHS percentiles showed the highest AD incidence rates. PHS predicted longitudinal 
clinical decline among older individuals with moderate to high CERAD (amyloid) and Braak (tau) 
scores at autopsy, even among APOE ε4 non-carriers. Beyond APOE, PHS may help identify 
asymptomatic individuals at highest risk for developing Alzheimer’s neurodegeneration.
Keywords
polygenic risk; preclinical AD
INTRODUCTION
There is increasing consensus that the pathobiological changes associated with late-onset 
Alzheimer’s disease (AD) begin years if not decades before the onset of dementia 
symptoms.1,2 Identification of cognitively asymptomatic older adults at elevated risk for AD 
dementia (i.e. those with preclinical AD) would aid in evaluation of new AD therapies.2 
Genetic information, such as presence of the ε4 allele of apolipoprotein E (APOE) can help 
identify individuals who are at higher risk for AD dementia.3 Longitudinal studies have 
found that APOE ε4 status predicts decline to mild cognitive impairment (MCI) and 
dementia4, and steeper cognitive decline in cognitively normal individuals5.
Beyond APOE ε4 carrier status, recent genetic studies have identified numerous single 
nucleotide polymorphisms (SNPs), each of which is associated with a small increase in AD 
dementia risk.6 Using genome-wide association (GWAS) from AD cases and controls, we 
have recently developed a novel ‘polygenic hazard score’ (PHS) for predicting age-specific 
risk for AD dementia that integrates 31 AD-associated SNPs (in addition to APOE) with 
US-population based AD dementia incidence rates.7 Among asymptomatic older adults, in 
retrospective analyses, we have previously shown that the PHS predicted age of AD onset 
strongly correlates with the actual age of onset.7 To evaluate clinical usefulness and further 
validate PHS, in this study, we prospectively evaluated whether PHS predicts rate of 
progression to AD dementia and longitudinal cognitive decline in cognitively asymptomatic 
older adults and individuals with MCI.
METHODS
We evaluated longitudinal clinical and neuropsychological data (from March 2016) from the 
National Alzheimer’s Coordinating Center (NACC).8 Using the NACC uniform dataset, we 
focused on older individuals classified at baseline as cognitively normal (CN), with a 
Clinical Dementia Rating9 (CDR) of 0 and available genetic information (n =1,081, Table 
1). We also evaluated older individuals classified at baseline as MCI (CDR = 0.5) with 
available genetic information (n = 571, Table 1). We focused on CN and MCI individuals 
with age of AD dementia onset < age 88 to avoid violations of Cox proportional hazards 
assumption as evaluated using scaled Schoenfeld residuals (total n = 1,652). The 
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institutional review boards of all participating institutions approved the procedures for all 
ADGC and NIA ADC sub-studies. Written informed consent was obtained from all 
participants or surrogates.
For each CN and MCI participant in this study, we calculated their individual PHS, as 
previously described7. In brief, we identified AD associated SNPs (at p < 10−5) using 
genotype data from 17,008 AD cases and 37,154 controls from Stage 1 of the International 
Genomics of Alzheimer’s Disease Project. Next, we selected a final total of 31 SNPs based 
on a stepwise Cox proportional hazards models using genotype data from 6,409 AD patients 
and 9,386 older controls from Phase 1 of the Alzheimer’s Disease Genetics Consortium 
(ADGC Phase 1). We corrected the resulting scores for each individual for the baseline allele 
frequencies using European genotypes from 1000 Genomes Project to derive a PHS for each 
participant. Finally, by combining US population based incidence rates, and genotype-
derived PHS for each individual, we derived estimates of instantaneous risk for developing 
AD, based on genotype and age. In this study, the PHS computed for every CN and MCI 
participant represents the vector product of an individual’s genotype for the 31 SNPs and the 
corresponding parameter estimates from the ADGC Phase 1 Cox proportional hazard model 
in addition to the APOE effects (for additional details see 7).
We first investigated the effects of the PHS on progression to AD dementia by using a Cox 
proportional hazards model, with time to event indicated by age of AD dementia onset. We 
resolved ‘ties’ using the Breslow method. We co-varied for effects of sex, APOE ε4 status 
(binarized as having at least 1 ε4 allele versus none), education and age at baseline. To 
prevent violating the proportional hazards assumptions, we additionally included baseline 
age stratified by quintiles as a covariate.10
Next, we employed a linear mixed-effects (LME) model to evaluate the relationship between 
PHS and longitudinal clinical decline as assessed by change in CDR-Sum of Boxes (CDR-
SB) as well as by change in Logical Memory test (LMT), Wechsler Adult Intelligence Scale 
- Revised (WAIS-R) Digit Symbol, the Boston Naming Test (BNT), Trail-Making Tests A 
and B (TMTA/B), forward and backward Digit Span (f/b DST) tests. To maintain consistent 
directionality across all tests, we inverted the scale for Trail-Making tests such that lower 
scores represent decline. We co-varied for sex, APOE ε4 status, education, baseline age and 
all their respective interactions with time. We were specifically interested in the PHS × time 
interaction, whereby a significant interaction indicates differences in rates of decline, as a 
function of differences in PHS. We then examined the main effect of PHS by comparing 
slopes of cognitive decline over time in the neuropsychological tests for individuals with 
high (~84 percentile) and low PHS (~16 percentile), defined by 1 standard deviation above 
or below the mean of PHS respectively.11 We also compared goodness of fit between the 
LME models with and without PHS using likelihood ratio tests to determine if PHS LME 
models resulted in a better fit than non-PHS LME models..
Finally, we evaluated the relationship between PHS, APOE and neuropathology in 
preclinical AD. Specifically, we conducted LME analysis assessing longitudinal change in 
CDR-SB in CN individuals with available neuropathology (specifically, neuritic plaque 
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scores based on the Consortium to Establish a Registry for AD (CERAD) and neurofibrillary 
tangle scores assessed with Braak stages).
RESULTS
PHS significantly predicted risk of progression from CN to AD dementia (hazard ratio (HR) 
= 2.36, 95% confidence interval (CI) = 1.38 – 4.03, p = 1.66×10−3) illustrating that 
polygenic information beyond APOE ε4 can identify asymptomatic older individuals at 
greatest risk for developing AD dementia. Individuals in the highest PHS decile had the 
highest annualized AD incidence rates (Figure 1). PHS also significantly influenced risk of 
progression to AD dementia in MCI individuals (HR = 1.17, 95% CI = 1.02 – 1.35, p = 
2.36×10−2). Using the combined CN and MCI cohorts (total n = 1,652) to maximize 
statistical power, we found that PHS significantly predicted risk of progression from CN and 
MCI to AD dementia (HR = 1.31, 95% CI = 1.14 – 1.51, p = 1.82×10−4). At 50% risk for 
progressing to AD dementia, the expected age for developing AD dementia is approximately 
85 years for an individual with low PHS (~16 percentile); however, for an individual with 
high PHS (~84 percentile), the expected age of onset is approximately 78 years. In all Cox 
models, the proportional hazard assumption was valid for all covariates.
Evaluating clinical progression and cognitive decline within the CN individuals, we found 
significant PHS by time interactions for CDR-SB (β = 0.05, standard error (SE) = 0.02, p = 
3.64×10−4), WAIS-R (β = −0.61, SE = 0.30, p = 4.25×10−2), TMTB (β = −2.48, SE = 0.99, 
p = 1.20×10−2), and fDST test (β = −0.93, SE = 0.45, p = 3.76×10−2) (Supplemental Table 
1), with significantly steeper slopes for high PHS individuals for WAIS-R, TMTB, and 
CDR-SB (Supplemental Table 2, Figure 2). Evaluating average percentage change across all 
neuropsychological tests, we found that PHS predicted cognitive decline (β = 0.84, SE = 
0.30, p = 4.50×10−3), with high PHS individuals showing greater rates of decline (β = 
−1.80, SE = 0.89, p = 4.30×10−2) compared to low PHS individuals (β = −0.12, SE = 0.80, p 
= 0.88). Goodness of fit comparison using likelihood ratio tests showed that the full LME 
model comprising PHS and covariates resulted in a better model fit for predicting decline in 
CDR-SB, BNT, WAIS-R, fDST and TMTB (Supplemental Table 3). We found similar 
results within the MCI individuals and the combined CN and MCI cohort (Supplemental 
Tables 1–7) illustrating that polygenic information beyond APOE ε4 can identify 
asymptomatic and mildly symptomatic individuals at highest risk for clinical and cognitive 
decline.
Finally, among CN individuals with moderate and frequent CERAD “C” score at autopsy, 
we found that PHS predicted change in CDR-SB over time (β = 1.25, SE = 0.28, p = 
6.63×10−6), with high PHS individuals showing a greater rate of increase (β = 5.62, SE = 
0.92, p = 1.23×10−9). In a reduced model without PHS, APOE ε4 status did not predict 
change in CDR-SB (β = 0.26, SE = 0.50, p = 0.61). Furthermore, even in APOE ε4 non-
carriers, PHS predicted change in CDR-SB over time (β = 2.11, SE = 0.38, p = 3.06×10−8), 
with high PHS individuals showing a greater rate of increase (β = 6.11, SE = 1.08, p = 
1.60×10−8). Similarly, among CN individuals with Braak stage III – IV at autopsy, PHS 
predicted change in CDR-SB over time (β = 0.93, SE = 0.24, p = 1.11×10−4), with high PHS 
individuals showing a greater rate of increase (β = 3.98, SE = 0.79, p = 4.45×10−7).
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DISCUSSION
Here, we show that PHS predicts time to progress to AD dementia and longitudinal 
cognitive decline in both preclinical AD and MCI. Among CN individuals with moderate to 
high CERAD and Braak scores at autopsy, we found that PHS predicted longitudinal clinical 
decline, even among APOE ε4 non-carriers. Beyond APOE, our findings indicate that PHS 
can be useful to identify asymptomatic older individuals at greatest risk for developing AD 
neurodegeneration.
These results illustrate the value of leveraging the polygenic architecture of the Alzheimer’s 
disease process. Building on prior work4,5, our findings indicate that polygenic information 
may be more informative than APOE for predicting clinical and cognitive progression in 
preclinical AD. Although prior studies have used polygenic risk scores in preclinical 
AD,12–14 by focusing on maximizing differences between ‘cases’ and ‘controls’, this 
approach is clinically suboptimal for assessing an age dependent process like AD dementia 
where a subset of ‘controls’ will develop dementia over time (see Figure 1). Furthermore, 
given the bias for selecting diseased cases and normal controls, baseline hazard/risk 
estimates derived from GWAS samples cannot be applied to older individuals from the 
general population.15 By employing an age-dependent, survival analysis framework and 
integrating AD-associated SNPs with established population-based incidence rates16, PHS 
provides an accurate estimate of age of onset risk in preclinical AD.
In our neuropathology analyses, PHS predicted longitudinal clinical decline in older 
individuals with moderate to high amyloid or tau pathology indicating that PHS may serve 
as an enrichment strategy for secondary prevention trials. Congruent with recent findings 
that the risk of dementia among APOE ε4/4 is lower than previously estimated17, among 
CNs with moderate to high amyloid load, we found that APOE did not predict clinical 
decline and PHS predicted change in CDR-SB even among APOE ε4 non-carriers. Our 
combined findings suggest that beyond APOE, PHS may prove useful both as a risk 
stratification and enrichment marker to identify asymptomatic individuals most likely to 
develop Alzheimer’s neurodegeneration.
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Figure 1. 
Annualized or cumulative incidence rates in CN individuals showing the instantaneous 
hazard as a function of PHS percentiles and age.
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Figure 2. 
Differences in change over time in CDR-SB in CN individuals over time for low (−1 SD, 
~16 percentile) and high (+1 SD, ~84 percentile) polygenic hazard score (PHS) individuals. 
Dotted lines around fitted line indicate estimated standard error.
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Table 1
Cohort demographics
CN (n = 1,081) MCI (n = 571)
Age ± SD 71·19 (6·65) 74·70 (5·85)
Education ± SD 16·07 (2·57) 15·70 (2·91)
Sex (% Female) 719 (66·51) 291 (50·96)
APOE ε4 carriers (%) 297 (27·47) 347 (60·77)
Converted to AD dementia (%) 38 (3·52) 390 (68·30)
Baseline MMSE ± SD 29·22 (1·05) 25.67 (3·36)
MMSE: Mini–Mental State Examination
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